Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Leuk Res. 2019 Jul 3;84:106180. doi: 10.1016/j.leukres.2019.106180

Figure 5.

Figure 5.

(A) Schematic summarizing observed effects of NCI34255 on Akt induced proliferation and survival of AML cells. Treatment with NCI34255 reduces the effects of EC activation through Akt signaling (blue lines) resulting in decreased proliferation and enhanced apoptosis (in the presence of Ara-C) of AML cells. (B) The impact of EC activation on adherent and non-adherent AML cell populations is shown. Adherent cells become quiescent and chemoresistant implicating them in relapse. Non-adherent cells show significant expansion and chemoresistance following EC activation identifying them as the cellular source for enhanced leukemia cellularity. Therapies aimed at targeting this process may provide new avenues for the optimal treatment of patients with AML.